01
Cash & equivalents increased 185.8%
Cash & equivalents changed +185.8% from the comparable as-filed period.
$152.9M→$437.1MComparable → current
· Biological Products, (No Diagnostic Substances)
RESEARCH SNAPSHOTScholar Rock Holding Corp's latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +185.8% from the comparable as-filed period.
Net income changed +0.1% from the comparable as-filed period.
Operating income changed +2.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SRRK · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001104659-26-091702SEC ↗10-QAug 6, 2026Period Jun 30, 20260001193125-26-336732SEC ↗8-KAug 6, 2026Period Aug 6, 20260001193125-26-336715SEC ↗4Jul 6, 2026Period Jul 1, 20260001193125-26-296252SEC ↗4Jul 6, 2026Period Jul 1, 20260001193125-26-296251SEC ↗4Jul 6, 2026Period Jul 1, 20260001193125-26-296248SEC ↗4Jul 6, 2026Period Jul 1, 20260001193125-26-296247SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 1, 2026Filed Jul 6, 2026 | FLIER JEFFREY S.Director | Open Market SaleDirect | 1,568 | $54 | $83,939 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | FLIER JEFFREY S.Director | Open Market SaleDirect | 1,470 | $54 | $79,728 | Form 4 ↗ |
| Jul 1, 2026Filed Jul 6, 2026 | FLIER JEFFREY S.Director | Open Market SaleDirect | 15 | $55 | $823 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed -6.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Stock-based compensation changed -19.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-296245